S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/RA Capital Management/Q2 2026

RA Capital Management

Period: Q2 2026 Β· Filed: 2026-08-14
View on SEC EDGAR β†—
AUM
$11.51B
Total portfolio value
Positions
84
Reported securities
Top Holding
ASND
23.8% $2.74B
QoQ Changes
+8 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2026-08-14) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
ASNDASCENDIS PHARMA A/S$2.74B23.83%$266.72$248.50-6.8%
23.8%
PARABILIS MEDICINES INC$791.9M6.88%β€”β€”
6.9%
RYTMRHYTHM PHARMACEUTICALS INC$740.2M6.43%$111.03$115.48+4.0%
6.4%
PCVXVAXCYTE INC$667.0M5.80%$58.13$58.07-0.1%
5.8%
SIONSIONNA THERAPEUTICS INC$435.7M3.79%$43.99$6.46-85.3%
3.8%
TYRATYRA BIOSCIENCES INC$389.6M3.39%$31.94$25.29-20.8%
3.4%
EWTXEDGEWISE THERAPEUTICS INC$341.0M2.96%$40.63$44.17+8.7%
3.0%
NAMSNEWAMSTERDAM PHARMA CO NV$323.7M2.81%$33.89$26.98-20.4%
2.8%
COAGHEMAB THERAPEUTICS HOLDINGS$286.8M2.49%$36.73$54.94+49.6%
2.5%
SEPNSEPTERNA INC$234.3M2.04%$33.49$44.50+32.9%
2.0%
BCAXBICARA THERAPEUTICS INC$215.4M1.87%$29.69$24.28-18.2%
1.9%
MLYSMINERALYS THERAPEUTICS INC$207.6M1.80%$26.98$25.64-5.0%
1.8%
GHRSGH RESEARCH PLC$205.3M1.78%$26.88$29.49+9.7%
1.8%
IRONDISC MEDICINE INC$179.2M1.56%$73.14$78.84+7.8%
1.6%
SGPSPYGLASS PHARMA INC$178.6M1.55%$22.26$26.20+17.7%
1.6%
ARTVARTIVA BIOTHERAPEUTICS INC$174.2M1.51%$9.70$11.45+18.0%
1.5%
JANXJANUX THERAPEUTICS INC$171.9M1.49%$15.36$16.12+5.0%
1.5%
TSHATAYSHA GENE THERAPIES INC$160.4M1.39%$6.81$5.95-12.6%
1.4%
BCRXBIOCRYST PHARMACEUTICALS INC$158.3M1.38%$10.00$9.74-2.6%
1.4%
WVEWAVE LIFE SCIENCES LTD$156.7M1.36%$5.81$5.41-6.9%
1.4%
NUVLNUVALENT INC-A$153.9M1.34%β€”β€”
1.3%
ABVXABIVAX SA-ADR$150.9M1.31%$133.26$118.96-10.7%
1.3%
ORKAORUKA THERAPEUTICS INC$147.9M1.29%$95.17$111.04+16.7%
1.3%
CLYMCLIMB BIO INC$147.4M1.28%$13.04$16.33+25.2%
1.3%
SLDBSOLID BIOSCIENCES INC$120.2M1.04%$9.99$9.20-7.9%
1.0%
ZLABZAI LAB LTD-ADR$109.1M0.95%$19.00$25.90+36.3%
0.9%
SPRYARS PHARMACEUTICALS INC$87.0M0.76%$8.01$5.65-29.5%
0.8%
XNCRXENCOR INC$84.9M0.74%$16.10$23.34+45.0%
0.7%
JBIOJADE BIOSCIENCES INC$81.6M0.71%$22.22$24.71+11.2%
0.7%
NTLAINTELLIA THERAPEUTICS INC$76.6M0.67%$16.92$11.91-29.6%
0.7%

Quarter-on-Quarter Activity

Q2 2026 vs. Q1 2026

New Positions (8)

TickerIssuerNotionalSince Filing
ASNDASCENDIS PHARMA A/S$2.74B-6.8%
PARABILIS MEDICINES INC$791.9M
COAGHEMAB THERAPEUTICS HOLDINGS$286.8M+49.6%
ABVXABIVAX SA-ADR$150.9M-10.7%
ORKAORUKA THERAPEUTICS INC$147.9M+16.7%
NTLAINTELLIA THERAPEUTICS INC$76.6M-29.6%
DFTXDEFINIUM THERAPEUTICS INC$70.6M
SANASANA BIOTECHNOLOGY INC$65.4M

Exited Positions (8)

TickerIssuerNotionalSince Filing
ASNDASCENDIS PHARMA A/S - ADR$2.35B-6.8%
DNTHDIANTHUS THERAPEUTICS INC$219.2M
PRAXPRAXIS PRECISION MEDICINES I$120.4M
SRPTSAREPTA THERAPEUTICS INC$84.9M
SYRESPYRE THERAPEUTICS INC$81.8M
FULCFULCRUM THERAPEUTICS INC$46.4M
OLMAOLEMA PHARMACEUTICALS INC$38.8M
DSGNDESIGN THERAPEUTICS INC$31.6M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
ACRSACLARIS THERAPEUTICS INC$41.8M+87.0%
ARTVARTIVA BIOTHERAPEUTICS INC$110.7M+82.2%+18.0%
AVTXAVALO THERAPEUTICS INC$8.6M+50.8%
ACRVACRIVON THERAPEUTICS INC$10.2M+46.6%
SLDBSOLID BIOSCIENCES INC$53.0M+28.9%-7.9%
XNCRXENCOR INC$25.9M+7.7%+45.0%
RZLTREZOLUTE INC$21.1M+2.9%
BIOABIOAGE LABS INC$12.1M+1.3%

Trimmed (8)

TickerIssuerNotionalShares Ξ”Since Filing
HOWLWEREWOLF THERAPEUTICS INC$-4.7M-64.3%
VORVOR BIOPHARMA INC$-52.2M-55.6%
NUVLNUVALENT INC-A$-105.7M-50.8%
GERNGERON CORP$-40.2M-32.9%
ACETADICET BIO INC$0.0M-21.1%
EWTXEDGEWISE THERAPEUTICS INC$12.5M-19.5%+8.7%
AKTSAKTIS ONCOLOGY INC$15.5M-12.6%
PTNPALATIN TECHNOLOGIES INC$-0.6M-11.3%
← Back to Hedge Funds